“…Furthermore, cardiac calcification at the mitral annulus is a process possessing characteristics of both atherosclerotic plaque calcification and media calcification [ 13 ]. In general, the process of arterial calcification has three important pathological characteristics (i) loss of circulating calcification inhibitors (i.e., pyrophosphate (PP i ), (vitamin K-dependent) carboxylated matrix gla protein and fetuin-A) [ 14 , 15 ], (ii) gain of circulating calcification stimulators (i.e., hyperphosphatemia, hypercalcemia and uremic toxins) [ 15 , 16 ] and (iii) the ability of vascular cells, i.e., vascular smooth muscle cells (VSMCs) in the (medial or intimal) arterial wall or valve interstitial cells (VICs) in aortic valves, to transdifferentiate into bone-like cells which goes along with upregulation of osteo/chondrogenic marker genes such as Runt-related transcription factor 2 (Runx2), tissue non-specific alkaline phosphatase (TNAP), Bone morphogenetic protein 2 (BMP2) and SRY-Box transcription factor 9 (Sox9). These bone-like cells produce and release calcified matrix vesicles, in which calcium and phosphate is built up, into the extracellular matrix resulting into mineralization of the surrounding tissue [ 15 , 16 ].…”